H 89 2HCl: Selective Protein Kinase A Inhibitor for Precision cAMP/PKA Signaling Research

Executive Summary: H 89 2HCl is a small-molecule inhibitor with a Ki of 48 nM for PKA under cell-free conditions, offering approximately 10-fold selectivity for PKA over PKG and over 500-fold selectivity compared to PKC, MLCK, and other kinases (APExBIO). It blocks cAMP-dependent protein phosphorylation without altering intracellular cAMP levels, as verified in PC12D cells. The compound has been used to dissect PKA/CREB signaling in osteoclastogenesis and neuronal models, demonstrating robust inhibition of forskolin-induced neurite outgrowth and histone IIb phosphorylation (Wang et al., 2021). H 89 2HCl is supplied as a solid, is soluble in DMSO (≥51.9 mg/mL), and is recommended for storage at -20°C (APExBIO). Its use is intended exclusively for research purposes, not for diagnostic or therapeutic applications.

Biological Rationale

cAMP-dependent protein kinase A (PKA) is a central regulator of cellular signaling. PKA modulates gene transcription, cytoskeletal dynamics, metabolism, and neuronal plasticity. Dysregulation of PKA signaling is implicated in multiple pathological states, including neurodegenerative diseases, certain cancers, and metabolic bone disorders (Wang et al., 2021). Pharmacological tools that selectively target PKA are essential for dissecting its role in specific pathways. H 89 2HCl, also known as N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide dihydrochloride, enables targeted inhibition of PKA-mediated phosphorylation events. Its selectivity profile minimizes off-target effects common with less discriminating kinase inhibitors (contrast: protocol-focused summary).

Mechanism of Action of H 89 2HCl

H 89 2HCl acts as a competitive inhibitor at the ATP-binding site of protein kinase A. In biochemical assays, it exhibits a Ki of 48 nM for PKA, demonstrating potent inhibition (APExBIO). The compound is approximately 10-fold more selective for PKA than for PKG and over 500-fold more selective than for kinases such as PKC, MLCK, calmodulin kinase II, and casein kinase I/II. H 89 2HCl also inhibits kinases including S6K1 (IC50 ≈ 80 nM), MSK1, ROCKII, PKBα, and MAPKAP-K1b, with reported IC50 values ranging from 80 nM to 2,800 nM (assay conditions: cell-free, 25°C, pH 7.4). The compound blocks cAMP-dependent protein phosphorylation, without affecting cAMP synthesis or degradation. In PC12D cells, H 89 2HCl suppresses forskolin-induced neurite outgrowth and histone IIb phosphorylation in a dose-dependent manner (Wang et al., 2021). This mode of action provides mechanistic precision for researchers interrogating PKA-driven signaling networks (extends: systems-biology perspective).

Evidence & Benchmarks

• H 89 2HCl inhibits PKA with a Ki of 48 nM in cell-free assays at 25°C, pH 7.4 (APExBIO).
• The inhibitor demonstrates 10-fold selectivity for PKA over PKG (B2190 datasheet, APExBIO).
• H 89 2HCl shows >500-fold selectivity against kinases such as PKC, MLCK, CaMKII, and casein kinase I/II (see Table 1 in Wang et al., 2021).
• In PC12D neuronal cells, H 89 2HCl dose-dependently suppresses forskolin-induced neurite outgrowth (n = 3, 37°C, 5% CO₂) (Wang et al., 2021).
• In osteoclastogenesis models, inhibition of PKA by H 89 blocks CREB phosphorylation, confirming pathway specificity (Wang et al., 2021).
• Solubility of H 89 2HCl is ≥51.9 mg/mL in DMSO at 20°C; it is insoluble in water and ethanol (APExBIO).

Applications, Limits & Misconceptions

H 89 2HCl is widely used for dissecting cAMP/PKA signaling in neurobiology, oncology, and bone biology. In neurodegenerative disease models, it enables isolation of PKA-dependent phosphorylation events and downstream gene expression changes (expands: mechanistic depth and translational focus). In osteoclastogenesis assays, H 89 2HCl helps clarify the role of PKA in CREB-mediated differentiation. It is also used for determining PKA involvement in cancer cell signaling. However, its inhibition profile includes modest off-target effects on kinases such as S6K1 and MSK1 at higher concentrations. H 89 does not inhibit adenylate cyclase or affect cAMP production directly, making it suitable for studies requiring specific blockade of PKA activity (clarifies: best practices and troubleshooting).

Common Pitfalls or Misconceptions

• H 89 2HCl is not a universal kinase inhibitor; it exhibits minimal activity against most non-PKA kinases below 1 μM.
• The compound does not reduce intracellular cAMP levels and is ineffective for studies requiring inhibition of cAMP synthesis.
• At high concentrations (>10 μM), modest off-target inhibition of S6K1, MSK1, and ROCKII can occur; careful titration is essential.
• H 89 2HCl is not suitable for in vivo diagnostic or therapeutic use; it is intended for research applications only (APExBIO).
• Incorrect solvent use (water or ethanol) results in precipitation and loss of activity; DMSO is required for stock solution preparation.

Workflow Integration & Parameters

For optimal use, H 89 2HCl should be dissolved in DMSO at concentrations up to 51.9 mg/mL. Stock solutions should be aliquoted and stored at -20°C, protected from light, and used within one month. In cell-based assays, typical working concentrations range from 0.1 to 10 μM, depending on model sensitivity and endpoint. The compound is compatible with standard kinase activity assays, western blotting for phospho-proteins, and phenotypic assays such as neurite outgrowth or osteoclastogenesis. Rapid addition to pre-warmed media is recommended to avoid precipitation. Users are advised to include DMSO-only vehicle controls in all experiments. For detailed troubleshooting and advanced optimization strategies, refer to this protocol-focused guide, which this article extends by providing updated selectivity data and application boundaries.

Conclusion & Outlook

H 89 2HCl, supplied by APExBIO, remains a gold-standard tool for selective inhibition of protein kinase A in research settings. Its robust selectivity profile and validated use in both neuronal and bone models make it indispensable for mechanistic dissection of cAMP/PKA pathways. Future research may leverage H 89 2HCl to explore complex disease networks, provided that concentration-dependent off-targets are controlled. For ordering and full specifications, consult the H 89 2HCl product page. Researchers are encouraged to review recent literature for emerging applications in translational disease models.